1. People's Republic of China Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
Guizhou Xinbang Pharmaceutical Co., Ltd.

Guizhou Xinbang Pharmaceutical Co., Ltd.

002390.SZ
Guizhou Xinbang Pharmaceutical Co., Ltd.CN flagShenzhen Stock Exchange
2.72
CNY
+0.02
- -
5.29BMarket Cap
Guizhou Xinbang Pharmaceutical Co., Ltd.
002390.SZ
(Shenzhen Stock Exchange)

Recent

price

2.72

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
0.41
0.42
0.52
0.68
2.22
3.36
3.14
3.57
4.06
4.22
3.71
3.56
3.4
3.37
3.17
- -
3.07
Revenue per Share
0.05
0.05
0.06
0.05
0.13
0.14
0.15
0.19
-0.8
0.15
0.11
0.15
0.12
0.15
0.05
- -
0.05
Basic EPS, GAAP
-0.09
-0.16
-0.1
-0.08
-0.43
-0.22
-0.38
-0.14
-0.3
0.43
0.38
0.11
0.23
0.34
0.27
- -
-0.06
Free Cash Flow per Basic Share
- -
0.04
0.03
0.03
0.08
0.12
0.11
0.11
0.16
0.13
0.13
0.13
0.09
0.08
0.1
- -
0.07
Dividend per Share
0.32
0.42
0.46
0.5
0.78
1.41
1.47
1.59
0.8
0.97
1.07
1.26
1.24
1.29
1.26
- -
1.29
Book Value per Share
1.21
1.13
1.12
1.15
1.5
1.49
2.33
2.44
2.51
2.52
2.75
3.3
3.34
3.32
3.27
- -
3.25
Tangible Book Value per Share
787
853
854
838
1,114
1,246
1,640
1,681
1,621
1,575
1,577
1,819
1,870
1,915
1,902
1,897
1,901
Basic Weighted Avg Shares
319
362
448
569
2,476
4,180
5,157
6,002
6,580
6,655
5,846
6,472
6,350
6,461
6,032
- -
5,831
Sales/Revenue/Turnover
12.06
11.8
10.76
8.39
9.73
7.31
7.68
8.77
7.67
7.83
7.7
8.74
5.99
7.18
5.68
- -
5.45
Operating Margin (%)
7
7
8
20
50
127
150
175
215
238
232
247
244
237
218
- -
- -
Depreciation Expense
38
46
48
40
145
174
246
319
-1,297
236
174
273
224
287
101
- -
94
Net Income, GAAP
14.87
14.29
17.08
16.96
22.7
26.2
22.21
20.91
- -
20.44
17.53
11.2
14.4
10.67
16.07
- -
17.9
Effective Tax Rate (%)
11.85
12.73
10.69
7.07
5.85
4.17
4.77
5.32
-19.7
3.55
2.97
4.22
3.53
4.45
1.68
- -
1.61
Profit Margin (%)
755
692
655
627
616
55
1,358
1,464
1,336
1,166
1,621
2,822
3,119
3,353
3,445
- -
3,556
Working Capital
- -
- -
- -
- -
14
16
- -
298
323
299
25
25
22
21
181
- -
265
LT Debt
960
980
1,023
1,036
2,458
2,669
6,485
6,759
5,169
5,048
5,169
6,829
7,065
7,142
7,020
- -
6,972
Total Equity
4.3
3.24
3.3
3.05
6.63
4.86
4.32
4.24
- -
4.62
4.34
6.11
4.02
5.23
3.8
- -
3.41
Return on Invested Capital (%)
10.72
11.2
9.8
7.98
11.07
7.8
7.32
6.61
- -
6.07
3.85
5.64
5.74
6.8
1.89
- -
1.67
Return on Capital (%)
16.61
15.05
12.81
9.99
22.57
13.29
11.82
12.59
-65.26
16.72
10.79
13.66
9.72
11.99
4.16
- -
3.8
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Dec'24
Mar'25
Jun'25
ST Debt
595
554
459
LT Borrowings
160
230
246
LT Finance Leases
21
19
19
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
1,944
1,944
1,944
Market Capitalization
8,922
7,070
6,614

Working Capital

FRC

•

in mil. unless spec.
Dec'24
Mar'25
Jun'25
Total Current Assets
5,252
5,275
5,086
Cash, Cash Equivalents & STI
1,016
985
999
Accounts Receivable, Net
2,534
2,596
2,481
Inventories
1,060
1,015
958
Total Current Liabilities
1,807
1,747
1,530
Payables & Accruals
- -
- -
- -
ST Debt
595
554
459
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
- -
- -
Free Cash Flow
- -
- -
- -
Net Income, GAAP
- -
- -
- -
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
1,582
1,464
1,519
1,467
6,032
2025
1,441
1,404
- -
- -
- -
2026
1,263
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.03
- -
- -
- -
0.05
2025
0.02
- -
- -
- -
- -
2026
0.03
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
0.1
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
Decibel Cannabis Company Inc. (DB.V)
Althea Group Holdings Limited (AGH.AX)
Bliss GVS Pharma Limited (BLISSGVS.BO)
Probiotec Limited (PBP.AX)
RLS Global AB (publ) (RLS.ST)
Dermapharm Holding SE (DMPHF)
Business
Guizhou Xinbang Pharmaceutical Co., Ltd. (002390.SZ) engages in the research, development, manufacture, and sale of pharmaceutical products primarily focused on anti-infective, nervous system, and cardiovascular drugs in China. The company offers a diverse portfolio of branded generics and innovative medicines, including cephalosporin antibiotics such as cefuroxime axetil tablets and cefixime capsules; quinolone antibiotics like levofloxacin hydrochloride tablets; nervous system drugs comprising olanzapine tablets, sertraline hydrochloride tablets, and sodium valproate sustained-release tablets; cardiovascular treatments such as torasemide tablets and clopidogrel hydrogen sulfate tablets; and other products including pantoprazole sodium enteric-coated tablets for gastrointestinal disorders and ambroxol hydrochloride oral solution for respiratory conditions. It operates manufacturing facilities in Guizhou province and distributes its products through a network of hospitals, pharmacies, and distributors across mainland China, with additional export activities to select Southeast Asian markets. Founded in 2001 and headquartered in Duyun, Guizhou province, China, the company functions as an independent entity listed on the Shenzhen Stock Exchange since 2010, serving healthcare providers, retailers, and patients in the domestic pharmaceutical sector. In recent developments, Guizhou Xinbang expanded its production capacity through the 2024 completion of a new sterile API facility in Guizhou, enhancing output for key injectables amid rising demand for anti-infectives. The company secured a strategic partnership with a leading domestic CDMO in early 2025 to co-develop generic versions of high-barrier patented drugs targeting the nervous system segment. Additionally, it launched Xinbang's upgraded flagship product, a novel fixed-dose combination of levofloxacin and beta-lactam antibiotics, in late 2024, strengthening its position in hospital tender markets.